277 related articles for article (PubMed ID: 34638136)
21. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
[TBL] [Abstract][Full Text] [Related]
23. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J
Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395
[TBL] [Abstract][Full Text] [Related]
24. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Cull G; Burger JA; Opat S; Gottlieb D; Verner E; Trotman J; Marlton P; Munoz J; Johnston P; Simpson D; Stern JC; Prathikanti R; Wu K; Novotny W; Huang J; Tam CS
Br J Haematol; 2022 Mar; 196(5):1209-1218. PubMed ID: 34915592
[TBL] [Abstract][Full Text] [Related]
25. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
26. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
29. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
30. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Casasnovas RO; Follows G; Zijlstra JM; Vermaat JSP; Kalakonda N; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi PF; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Chamoun K; Shah J; Canales M; Maerevoet M; Shacham S; Kauffman MG; Goy A
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):24-33. PubMed ID: 34493477
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Roschewski M; Patel MR; Reagan PM; Saba NS; Collins GP; Arkenau HT; de Vos S; Nuttall B; Acar M; Burke K; White RD; Udriste M; Sharma S; Dougherty B; Stetson D; Jenkins D; Mortlock A; Forcina A; Munugalavadla V; Flinn I
Clin Cancer Res; 2023 Sep; 29(17):3301-3312. PubMed ID: 37364001
[TBL] [Abstract][Full Text] [Related]
32. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
33. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
34. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
35. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P; Zhang H; Johnson R; Martín García-Sancho A; Provencio Pulla M; Trněný M; Yuen S; Tilly H; Kingsley E; Tumyan G; Assouline SE; Auer R; Ivanova E; Kim P; Huang S; Delarue R; Trotman J
J Clin Oncol; 2023 Nov; 41(33):5107-5117. PubMed ID: 37506346
[TBL] [Abstract][Full Text] [Related]
36. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
[TBL] [Abstract][Full Text] [Related]
37. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
38. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
40. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
